THE ATAXIA-TELANGIECTASIA SOCIETY — grant history
Latest income
£657k
Grants listed (FY2024)
2
Listed grants total
£64k
Accounts grants total
£60k
listed grants reconcile with the accounts totalextracted from its FY2024 accounts
What changed: FY2023 → FY2024
| Change | Grantee | FY2023 | FY2024 |
|---|---|---|---|
| new | Joint funding of 3 research projects* 1) Investigating the role of mutant Triple T chaperone in ATM assembly in Ataxia Telangiectasia: A structural perspective, 2) Identifying existing drugs to repurpose for Ataxia Telangiectasia, 3) Biomarkers for Babies and Young Children with Ataxia Telangiectasia | — | £60k |
| new | Statistics Consultancy | — | £4k |
| not listed | Modulation of RELB/p52 - dependent NF-kB activities to improve neurodegenerative symptoms of AT | £80k | — |
| not listed | Joint funding of 5 research projects | £30k | — |
| not listed | Functional and metabolomic analysis of iPSC-derived Purkinje neurons from AT patients | £30k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Joint funding of 3 research projects* 1) Investigating the role of mutant Triple T chaperone in ATM assembly in Ataxia Telangiectasia: A structural perspective, 2) Identifying existing drugs to repurpose for Ataxia Telangiectasia, 3) Biomarkers for Babies and Young Children with Ataxia Telangiectasia | FY2024 | £60k | Research |
| Statistics Consultancy | FY2024 | £4k | Research |
| Modulation of RELB/p52 - dependent NF-kB activities to improve neurodegenerative symptoms of AT | FY2023 | £80k | Research |
| Joint funding of 5 research projects | FY2023 | £30k | Research |
| Functional and metabolomic analysis of iPSC-derived Purkinje neurons from AT patients | FY2023 | £30k | Research |
| Joint funding of 5 research projects | FY2022 | £30k | 1) Brain-penetrating ATM gene therapy, 2) Study of natural killer cells in AT pathogenesis and their therapeutical implications, 3) Digital drug prediction informed by genetic analysis of stem cell-derived mini brains from AT patients, 4) Understanding and treating AT 5) Trial REadiness in AT |
| Natural History of Ataxia-Telangiectasia | FY2022 | £8k | Statistics Consultancy |
| Royal Papworth Hospital | FY2022 | £4k | the use of ultrasound (USS) in the assessment of people with Ataxia-Telangiectasia’s ability to swallow versus use of videofluoroscopic swallow studies (VFSS) |